Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.97%
#3 BankrCoin BankrCoin +19.53%
#4 Ankr Network Ankr Network +17.24%
#5 Hive Hive +16.87%
#6 StonkBroker StonkBroker +16.12%
#7 ICON ICON +13.08%
#8 Status Status +12.07%
#9 Prom Prom +9.87%
#10 Provenance Blockchain Provenance Blockchain +9.17%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc.

ARMP
Rank in Stocks #18285
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology... Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Share Price
$5.59
Last synced: 2026-09-02
Market Cap
$205.21M
Change (1 day)
6.27%
Change (1 year)
86.33%
Country
US
Trade Armata Pharmaceuticals, Inc. (ARMP)

Category

Healthcare
P/E ratio for Armata Pharmaceuticals, Inc. (ARMP)
P/E ratio as of 2026 TTM: 0
According to Armata Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Armata Pharmaceuticals, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.